YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has entered a licensing agreement with Shenyang Sunshine Pharmaceutical Co., Ltd. to commercialize Clifutinib Besylate in China. The agreement involves an upfront payment of RMB 60 million, with additional milestone payments contingent on certain achievements. This strategic move aims to leverage Clifutinib’s potential in the Chinese market, while the company retains rights outside of China.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.